Table 3.
Circulating miRNAs That Are Uniquely Differentially Regulated in AA Women with Early Stage Breast Cancer (Zhao et al., 2010)
| microRNA Name | Genomic Location | Up- or Downregulated | Validated Target mRNAs | Intronic/Intergenic |
|---|---|---|---|---|
| miR-425 | 3p21 | Up | CCND1 | DALRD3 |
| miR-483-5p | 11p15 | Up | SRF, MAPK3, FAM160B2, ALCAM | IGF2 |
| miR-485-3p | 14q32 | Up | NTRK3, NFYB, SLC40A1, MAT1A | Intergenic |
| miR-431 | 14q32 | Up | 0 | RTL1 (as) |
| miR-493 | 14q32 | Up | RHOC, MAP2K7, FZD4 | Intergenic |
| miR-558 | 2p22 | Up | 0 | BIRC6 |
| miR-331-5p | 12q22 | Up | 0 | Intergenic |
| miR-409-5p | 14q32 | Down | 0 | Intergenic |
| miR-642 | 19q13 | Down | DOHH | GIPR |
| miR-505 | Xq27 | Down | SRSF1 | ATP11C |
| miR-377 | 14q32 | Down | PPM1A, PAK1, SOD1, SOD2 | Intergenic |
| miR-340 | 5q35 | Down | MET | RNF130 |
| Let-7d | 9q22 | Down | HMGA2, APP, DICER, SLC11A2, PDGFA, IL13, MPL, EIF2C1, TNFRSF10B | Intergenic |
Genes that are validated targets of the identified miRNAs are based on those annotated in miRTarBase 2016 with either one or more strong evidence and two or more less strong evidence (Chou et al., 2016).